CY1121436T1 - Δοσολογια για τους αναστολεις των kinασων janus (jak) - Google Patents

Δοσολογια για τους αναστολεις των kinασων janus (jak)

Info

Publication number
CY1121436T1
CY1121436T1 CY20191100203T CY191100203T CY1121436T1 CY 1121436 T1 CY1121436 T1 CY 1121436T1 CY 20191100203 T CY20191100203 T CY 20191100203T CY 191100203 T CY191100203 T CY 191100203T CY 1121436 T1 CY1121436 T1 CY 1121436T1
Authority
CY
Cyprus
Prior art keywords
jak
mammal
janus
inhibitors
dosage
Prior art date
Application number
CY20191100203T
Other languages
Greek (el)
English (en)
Inventor
Andrea J. GONZALES
Sallie B. COSGROVE
Phyllis B. MALPAS
Michael Rolf STEGEMANN
Wendy Turner COLLARD
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121436(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CY1121436T1 publication Critical patent/CY1121436T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CY20191100203T 2012-07-20 2019-02-14 Δοσολογια για τους αναστολεις των kinασων janus (jak) CY1121436T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US201361815803P 2013-04-25 2013-04-25
PCT/US2013/051015 WO2014015107A1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Publications (1)

Publication Number Publication Date
CY1121436T1 true CY1121436T1 (el) 2020-05-29

Family

ID=48901189

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100203T CY1121436T1 (el) 2012-07-20 2019-02-14 Δοσολογια για τους αναστολεις των kinασων janus (jak)

Country Status (25)

Country Link
US (1) US9522151B2 (enExample)
EP (1) EP2874630B1 (enExample)
JP (2) JP6022063B2 (enExample)
KR (2) KR20150028299A (enExample)
CN (2) CN104470525A (enExample)
AU (1) AU2013292547B2 (enExample)
BR (1) BR112015000808A2 (enExample)
CA (1) CA2878867C (enExample)
CY (1) CY1121436T1 (enExample)
DK (1) DK2874630T3 (enExample)
ES (1) ES2707627T3 (enExample)
HK (2) HK1209314A1 (enExample)
HR (1) HRP20182088T1 (enExample)
HU (1) HUE042771T2 (enExample)
IN (1) IN2015DN00370A (enExample)
LT (1) LT2874630T (enExample)
MX (1) MX360857B (enExample)
NZ (1) NZ703152A (enExample)
PL (1) PL2874630T3 (enExample)
PT (1) PT2874630T (enExample)
RS (1) RS58242B1 (enExample)
SI (1) SI2874630T1 (enExample)
SM (1) SMT201900044T1 (enExample)
WO (1) WO2014015107A1 (enExample)
ZA (1) ZA201500134B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3290421B1 (en) 2013-02-22 2019-01-02 Pfizer Inc Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak)
EP3180344B1 (en) 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
SG10201913999PA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
WO2017143014A1 (en) 2016-02-16 2017-08-24 Brian Kim Jak inhibitors and uses thereof
CN107098908B (zh) 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3127892A1 (en) 2019-01-30 2020-08-06 Gargamel (Zhuhai) Biotech Ltd. Jak inhibitor and preparation method thereof
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
JP2023554665A (ja) 2020-12-18 2023-12-28 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド ホウ素含有ピラゾール化合物、それらを含む組成物、それらの方法及び使用
KR20220129494A (ko) * 2021-03-16 2022-09-23 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물의 신규 염 및 이들의 용도
WO2022222948A1 (zh) * 2021-04-22 2022-10-27 深圳微芯生物科技股份有限公司 包含jak3/jak1/tbk1选择性抑制剂的药物组合物及其医药用途
WO2024259429A2 (en) * 2023-06-16 2024-12-19 The University Of Chicago Methods and compositions for pharmaceutically relevant interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL198640B1 (pl) 1998-06-19 2008-07-31 Pfizer Prod Inc Związki pirolo[2,3-d]pirymidynowe, środek farmaceutyczny i zastosowanie tych związków
HRP20140395T1 (hr) 2008-08-20 2014-06-06 Zoetis Llc SPOJEVI PIROLO[2,3-d]PIRIMIDINA

Also Published As

Publication number Publication date
MX360857B (es) 2018-11-20
JP2015522620A (ja) 2015-08-06
LT2874630T (lt) 2019-02-11
CA2878867A1 (en) 2014-01-23
US9522151B2 (en) 2016-12-20
CN104470525A (zh) 2015-03-25
WO2014015107A1 (en) 2014-01-23
KR20170034949A (ko) 2017-03-29
US20150126535A1 (en) 2015-05-07
AU2013292547B2 (en) 2017-05-04
EP2874630A1 (en) 2015-05-27
HK1209314A1 (en) 2016-04-01
AU2013292547A1 (en) 2015-01-22
BR112015000808A2 (pt) 2017-06-27
SMT201900044T1 (it) 2019-02-28
CN108354938A (zh) 2018-08-03
KR20150028299A (ko) 2015-03-13
HUE042771T2 (hu) 2019-07-29
ZA201500134B (en) 2016-08-31
SI2874630T1 (sl) 2019-04-30
PL2874630T3 (pl) 2019-04-30
JP2017019816A (ja) 2017-01-26
IN2015DN00370A (enExample) 2015-06-12
NZ703152A (en) 2016-03-31
CA2878867C (en) 2018-01-09
EP2874630B1 (en) 2018-12-05
ES2707627T3 (es) 2019-04-04
RS58242B1 (sr) 2019-03-29
DK2874630T3 (en) 2019-01-28
HRP20182088T1 (hr) 2019-02-08
JP6022063B2 (ja) 2016-11-09
PT2874630T (pt) 2019-01-31
MX2015000871A (es) 2015-05-07
HK1252083A1 (zh) 2019-05-17

Similar Documents

Publication Publication Date Title
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1125436T1 (el) Αναστολεις dna-pk
CY1123631T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
IN2015DN00370A (enExample)
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
EA201491694A1 (ru) Лечение рака ингибиторами tor киназы
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
BR112014012607A2 (pt) métodos de tratamento usando um inibidor de interferon gama
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
MX373964B (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
MX2015006039A (es) Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer.
EA201391230A1 (ru) Соединения и композиции в качестве ингибиторов trk
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EP4116293A3 (en) Rho kinase inhibitors
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
CY1121710T1 (el) Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας
EA201591509A1 (ru) Ингибиторы cdc7
EA201490545A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ С-Kit
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων